MARKET

BTAI

BTAI

BIOXCEL THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.44
-0.03
-0.29%
After Hours: 10.44 0 0.00% 16:00 09/13 EDT
OPEN
10.49
PREV CLOSE
10.47
HIGH
10.86
LOW
10.20
VOLUME
26.82K
TURNOVER
--
52 WEEK HIGH
12.00
52 WEEK LOW
2.410
MARKET CAP
164.24M
P/E (TTM)
-5.9103
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BTAI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BTAI News

  • 71 Biggest Movers From Yesterday
  • Benzinga.3d ago
  • BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)
  • GlobeNewswire.09/04 13:00
  • BioXcel Therapeutics Receives FDA Orphan Drug Designation For BXCL701 For The Treatment Of Acute Myeloid Leukemia
  • Benzinga.09/04 12:09
  • BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defenses (DoD) Congressionally Directed Medical Research Programs (CDMRP) for Development of BXCL501
  • GlobeNewswire.08/20 13:00

More

Industry

Biotechnology & Medical Research
+0.20%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About BTAI

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.
More

Webull offers BioXcel Therapeutics Inc (BTAI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.